🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

54 results for “extended-release” Clear

  1. Aceneuramic Acid Extended-Release Tablets

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy

    phase 3 small molecule terminated

    1 trial

  2. Delayed and extended release mesalazine

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  3. Extended Release Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 3 small molecule completed

    1 trial

  4. Extended Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  5. Extended-release Guanfacine HCl (Intuniv, SPD503)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  6. Extended-release Guanfacine Hydrochloride

    Takeda

    Attention-deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    3 trials

  7. Placebo for Ralinepag extended-release tablets, Ralinepag, Ralinepag, Ralinepag

    United Therapeutics Europe Ltd

    Pulmonary arterial hypertension (PAH)

    phase 3 small molecule active

    1 trial

  8. Pramipexol Extended Release

    Boehringer Ingelheim

    Early Parkinson Disease (Early PD)

    phase 3 small molecule completed

    1 trial

  9. Rosiglitazone Extended Release 2mg

    GlaxoSmithKline

    Alzheimer's Disease

    phase 3 small molecule completed

    1 trial

  10. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  11. SPD476, MMX™ mesalazine, 1.2g extended release tablet

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  12. Zolpidem extended-release

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Addiction

    phase 3 small molecule completed

    1 trial

  13. aceneuramic acid extended-release (Ace-ER)

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy

    phase 3 small molecule completed

    1 trial

  14. extended-release guanfacine hydrochloride (SPD503)

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    1 trial

  15. extended-release naltrexone (XR-NTX)

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine-dependence

    phase 3 small molecule active

    1 trial

  16. Aceneuramic Acid Extended-Release

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy

    phase 2 small molecule terminated

    1 trial

  17. DCCR (diazoxide choline) extended-release tablets

    SOLENO THERAPEUTICS INC

    SH2B1 Deficiency Obesity

    phase 2 small molecule active

    1 trial

  18. Doxazosin Mesylate, Extended Release

    United Therapeutics Europe Ltd

    Stress Disorders, Post-Traumatic

    phase 2 small molecule active

    1 trial

  19. Doxazosin extended release

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine or Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  20. Extended-Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  21. Extended-release Onapristone

    Context Therapeutics

    Refractory Endometrial Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. GRANISETRON EXTENDED RELEASE INJECTION (GERSC)

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 2 small molecule terminated

    1 trial

  23. Gocovri (extended-release amantidine)

    SUPERNUS PHARMACEUTICALS, INC.

    Radiation Encephalopathy

    phase 2 small molecule active

    1 trial

  24. Mixed-Amphetamine Salts- Extended Release (MAS-ER)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources